Streptococcal infection is believed to have an intimate relationship with psoriasis, although the pathogenic role of streptococcal DNA is not fully understood. To gain a clearer understanding of these dynamics, we investigated the effect of streptococcal DNA on lymphocyte proliferation and activation as well as cytokine secretion in psoriasis. Peripheral blood mononuclear cells (PBMCs) from psoriatic patients had higher proliferative responses upon stimulation by streptococcal antigen (SA) when compared with those from healthy individuals. Strikingly, this enhanced proliferation of PBMCs was attenuated after administration of SA treated with DNase-I. In addition, CD69 expression levels on T cells, including skin-homing lymphocyte cutaneous lymphocyte-associated antigen positive T cells, and IFN-a secretion by PBMCs were also attenuated in patients after stimulation with SA without nucleic acid (non-nucleic acid SA, non-NASA) compared with stimulation with untreated SA. However, activation marker CD86 expression levels on B cells as well as the secretion of IFN-g and tumor necrosis factor (TNF)-a following stimulation with SA or non-NASA were not significantly altered. Interestingly, the attenuated T-cell activation and IFN-a secretion in psoriatic patients could be reconstituted when stimulated by non-NASA combined with synthetic CpG-A, but not when combined with synthetic CpG-B. This study demonstrates the integral function of SA, particularly streptococcal DNA, in the pathogenesis of psoriasis.
INTRODUCTION
Psoriasis is conventionally considered to be a T-cell-mediated T helper 1 (Th1)-type inflammatory skin disease characterized by hyperproliferative keratinocytes and infiltration of prominent T cells, dendritic cells (DCs), and neutrophils (Griffiths and Barker, 2007) . Intralesional T cells expressing the unique skin-homing determinant cutaneous lymphocyte-associated antigen (CLA) (Fuhlbrigge et al., 1997) , along with other immune cells such as DCs and neutrophils, induce the proliferation and abnormal differentiate of keratinocytes (Prinz, 2003; Bowcock and Krueger, 2005; Gaspari, 2006) . Recent studies have also shown that Th17 cells have an essential function during psoriatic pathogenesis (Wilson et al., 2007; Zheng et al., 2007) . þ T cells may collaboratively contribute to psoriasis development (Kryczek et al., 2008) . Although the pathogenesis of psoriasis is not fully understood, longtime clinical observation substantiates microbial infection's intimate relationship with onset. Group A streptococci (GAS) are a well-recognized trigger for acute guttate psoriasis and are involved in the exacerbation of chronic plaque psoriasis (Gudjonsson et al., 2003) . Increased peripheral blood mononuclear cell (PBMC) responses to the cell walls and membranes of GAS have been reported in both guttate and chronic plaque psoriasis cases as compared with control patients (Gross et al., 1977; Baker et al., 1991) . Furthermore, GAS-reactive T cells in skin lesions of chronic plaque psoriasis can proliferate in response to streptococcal antigens (SAs), producing IFN-g (Baker et al., 1999; Brown et al., 2000) . Recently, identical TCR rearrangements have also been found in streptococcal angina and skin lesions of patients with psoriasis vulgaris (Diluvio et al., 2006) . Therefore, infection, especially streptococcal infection, has been regarded as an initial factor in the activation of pathogenic T cells in psoriasis.
Thus far, most of the studies concerning the trigger mechanisms for streptococcal infection-related psoriasis have focused mainly on its protein antigens. Unfortunately, the identities of the SAs recognized by pathogenic T cells have yet to be determined. In addition to the bacterial proteins, the role of streptococcal DNA in psoriatic pathogenesis has also not been fully elucidated.
Bacterial DNA containing unmethylated nucleotides with the particular sequence motif CG has been recognized as an immune-stimulatory molecule triggering Th1-type responses and producing proinflammatory cytokines and chemokines via innate Toll-like receptor 9 (TLR-9) (Hemmi et al., 2000; Bauer et al., 2001; Bauer and Wagner, 2002; Krieg, 2002) . It has been reported that streptococcal DNA contains such stimulatory motifs, thereby inducing a strong immune reaction (Chatellier and Kotb, 2000; Oshikawa et al., 2006) . Recent studies also suggest that CpG DNA may contribute to the development and/or progression of some autoimmune and inflammatory diseases. For example, the anti-DNA autoantibodies in systemic lupus erythematosus patients cross-react with bacterial and mammalian DNA (Pisetsky et al., 1999) . Mice immunized with CpG DNA plus a chlamydia-derived antigen that cross-reacts with a cardiac antigen develop an autoimmune myocarditis (Bachmaier et al., 1999) . CpG DNA has also been shown to be important for establishing experimental autoimmune encephalomyelitis, an animal disease model of multiple sclerosis (Ichikawa et al., 2002; Prinz et al., 2006) .
For this study, we hypothesized that streptococcal CpG DNA may be critical in the pathogenesis of psoriasis. We examined the effects of streptococcal DNA on the proliferation, activation, and cytokine secretion of PBMCs in patients with psoriasis. The levels of PBMCs and T-cell proliferation and the activation of T cells, including CLA þ T cells, as well as the production of IFN-a in response to SA stimulation were found to decrease significantly when bacterial DNA was devoid of whole SA. However, B-cell activation was not influenced. These results suggest that streptococcal CpG DNA may function in the activation of pathogenic T cells, thus leading to the development of psoriasis. This provides new insights into the pathogenesis of psoriasis.
RESULTS
Proliferation of PBMCs in psoriatic patients is significantly higher than in healthy individuals on whole SA stimulation, but this increased proliferation is attenuated after administration of whole SA treated with DNase-I It has been shown that patients with guttate or chronic plaques show increased PBMC responses to GAS antigens (Gross et al., 1977; Baker et al., 1991) . We therefore examined the proliferative levels of PBMCs in psoriatic patients and healthy individuals in response to SA. As shown in Figure 1a , patient PBMCs indeed showed higher levels of proliferation in response to SA as compared with those from healthy individuals, and a significant difference occurred at a dose of 25 mg ml À1 (P ¼ 0.032, Figure 1a ). By contrast, the proliferative responses to non-nucleic acid streptococcal antigen (non-NASA) at any dose did not show significant differences between the patients and the controls (P40.05, Figure 1b) . To examine the net contribution of streptococcal DNA in PBMC proliferation, the number of counts per minute (c.p.m.) of PBMCs stimulated with whole SA treated with DNase-I was subtracted from the c.p.m. of PBMCs stimulated with whole SA. As indicated in Figure 1c , proliferation of PBMCs from psoriatic patients was significantly higher than that of those from healthy individuals at the dose of 25 mg ml À1 (P ¼ 0.022). These results affirm that streptococcal infection may be critical in the pathogenesis of psoriasis. To further assess the role of streptococcal DNA in the pathogenesis of psoriasis, we assessed PBMC proliferation when stimulated with whole SA or non-NASA. We found that the proliferation of PBMCs from psoriatic patients upon stimulation with any dose of non-NASA was significantly attenuated as compared with that stimulated by SA (Po0.001, Figure 2a ), whereas in PBMCs from healthy individuals, only lower doses of non-NASA induced significantly lower responses as compared with whole SA (P ¼ 0.002 and 0.016, respectively, Figure 2b ). Similar levels of proliferation were observed between the responses to non-NASA and SA at the dose of 25 mg ml À1 (P ¼ 0.510, Figure 2b ). The decreased proliferation is not due to DNase-I treatment as the addition of DNase-I-treated or untreated phytohemagglutinin induced similar levels of PBMC proliferation in cells from both patients and healthy individuals (P ¼ 0.165 and 0.099, respectively). These results suggest that streptococcal DNA may indeed participate in the process of immune response triggered by streptococcus in psoriasis.
Decreased T-cell proliferation, expression of CD69 on both whole T cells and CLA þ T cells, and IFN-a production upon stimulation with SA devoid of bacterial DNA in psoriatic patients' PBMCs Next, we examined the effect of streptococcal DNA on T-cell proliferation and activation, including the skin-homing CLA þ T-cell activation in psoriatic patients. We found that the proliferation of T cells from patients upon stimulation with non-NASA was significantly reduced as compared with that stimulated by SA (P ¼ 0.041, Figure 3a) . Furthermore, both SA and non-NASA induced the activation of whole T cells and CLA þ T cells as measured by CD69 expression (Figure 3b and c). However, stimulation of PBMCs from patients with SA resulted in upregulation of CD69 at 10.44% of whole T cells and 0.5% of CLA þ T cells compared with 9.24% of whole T cells and 0.35% of CLA þ T cells activated by SA devoid of bacterial DNA (P ¼ 0.012 and 0.042, respectively, Figure 3b and c). By contrast, there was no significant difference in CD69 expression on whole T cells from healthy individuals when stimulated with SA or non-NASA (7.08 vs 6.28%, P ¼ 0.181, Figure 3b ). Consistent with the result for whole T cells, similar levels of CD69 expression on CLA þ T cells were observed on stimulation with SA or non-NASA in healthy PBMCs (0.35 vs 0.32%, P ¼ 0.670, Figure 3c ).
It has been shown that bacterial DNA can activate B cells to proliferate, secrete IgM and cytokine IL-10, and upregulate surface molecule expression such as with HLA-DR and costimulatory molecules (Decker et al., 2000) . We examined the effects of streptococcal DNA on B cells regarding the expression of the co-stimulatory molecule CD86 in patient cells. No significant difference was found in the expression of CD86 on B cells induced by SA and by non-NASA (39.42 vs 40.27%, P ¼ 0.668, Figure 4a ) at 2 mg ml À1 SA stimulation. The cytokines IFN-a, IFN-g, and TNF-a have been shown to be important in psoriasis. Therefore, we examined the cytokine secretion produced by PBMCs from patients. Both SA and non-NASA induced significant levels of IFN-a, IFN-g, and TNF-a ( Figure 4b ). The stimulation of PBMCs with SA resulted in a significant amount of IFN-a production as compared with stimulation with non-NASA (P ¼ 0.003, Figure 4b ). However, the levels of IFN-g and TNF-a were similar when PBMCs were stimulated with SA or non-NASA (P40.05, Figure 4b ). Furthermore, we found that IFN-g was secreted mainly by T cells, and not plasmacytoid DCs (pDCs), in response to SA and non-NASA (Supplementary Figure S1a) . However, there was no significant difference between SA and non-NASA (2.07 vs. 1.71%, P ¼ 0.263, Supplementary Figure  S1b ). This is not very surprising given that pDCs are predominately type I IFN producers. Taken together, these results indicate that streptococcal DNA may aid in the activation of pathogenic T cells through IFN-a secretion, leading to the development of psoriasis. Neither CpG-A nor CpG-B alone appeared to activate whole T cells or CLA þ T cells as compared with the medium. In addition, non-NASA combined with CpG-A, but not with CpG-B, induced significantly higher levels of IFN-a production than did non-NASA stimulation alone (P ¼ 0.014, Figure  5c ). Because CpG-A mainly activates pDCs, we assume that streptococcal DNA may enhance the activation of pathogenic T cells through pDC activation and IFN-a production. To further investigate this hypothesis, we compared T-cell proliferation levels with SA in the presence or absence of pDCs in the patient cells. The proliferative responses to SA by T cells in the absence of pDCs were lower than those with the whole antigen-presenting cells. However, T cells still proliferated in the absence of pDCs (data not shown). In addition, it has been reported that pDCs in the peripheral blood of psoriatic patients significantly decreased compared with those in the blood of healthy individuals (Nestle et al., 2005) . In our study, we also observed a significantly lower frequency of pDCs in the peripheral blood from patients (0.58 vs 0.23%, P ¼ 0.014, Supplementary Figure S2a) . However, the levels of IFN-a secreted by PBMCs upon stimulation with SA were similar between cells from patients and cells from Figure S2b) . These results suggest that pDCs from psoriatic patients may have been activated, thus secreting large amounts of IFN-a.
DISCUSSION
In this study, we showed that PBMCs from psoriatic patients had significantly higher proliferation and T-cell activation upon SA stimulation. However, the enhanced proliferation and T-cell activation as well as IFN-a secretion were attenuated after stimulation with SA devoid of bacterial DNA. Strikingly, the decreased T-cell activation and IFN-a secretion could be reconstituted by stimulation with non-NASA combined with CpG-A but not when combined with CpG-B. These data suggest that streptococcal DNA indeed participates in the progress of pathogenic immune reaction triggered by streptococcus in psoriasis. We found that blood from psoriatic patients had significantly higher PBMC proliferation in response to SA stimulation than did that from healthy volunteers. In addition, psoriatic patients' cells showed pronounced response to streptococcal DNA stimulation, which may be related to increased expression of TLR-9 in patients (unpublished observation). This may also explain why we did not see any significant difference when PBMCs from either patients or healthy individuals were stimulated with non-NASA. Furthermore, we examined the effect of streptococcal DNA on T-cell proliferation and activation, including the skin-homing CLA þ T-cell activation. In patients, T-cell proliferation upon stimulation with non-NASA was significantly attenuated as compared with that stimulated by SA. Also, SA stimulation of PBMCs from patients resulted in significant upregulation of CD69 on whole T cells and CLA þ T cells compared with non-NASA stimulation. This is consistent with a previous report showing persistent CD69 expression on the local infiltrating T cells in psoriatic patients (Torres-Alvarez et al., 2007) . However, among healthy controls there was no significant difference in expression of CD69 on whole T cells and CLA þ T cells induced by SA and non-NASA. In addition, in contrast to psoriatic patients, neither SA nor non-NASA could activate CLA þ T cells in the blood from healthy volunteers. These results suggest that T cells from patients have a higher sensitivity to stimulation by streptococcal DNA. The increased T-cell proliferation and activation may correspond with disease development, as implicated by a previous report describing psoriatic patients as having a higher frequency of circulation CLA þ T cells, and they closely correlate with the severity of their disease (Sigmundsdottir et al., 2001) . Taken together, our findings show that streptococcal CpG DNA may participate in the development of psoriasis by increasing the activation of pathogenic T cells.
Interestingly, we found that the decreased activation of T cells stimulated by non-NASA alone could be reconstituted by the combined stimulation of non-NASA plus CpG-A, but not by combination with CpG-B. This result is not associated with the direct contribution of CpG-A because neither of them is able to trigger the activation of T cells directly. It has been shown that CpG-A predominantly activates pDCs and induces high levels of IFN-a production, whereas CpG-B is superior in activating B cells (Krieg, 2002; Vollmer et al., 2004) . Therefore, we speculate that streptococcal DNA may increase the activation of pathogenic T cells through the activation of pDCs and production of IFN-a. This notion is supported by a recent finding that IFN-a derived from pDCs activates and expands pathogenic T cells, causing the development of skin lesions such as psoriasis (Nestle et al., 2005) . In addition, IFN-a therapy has been reported to exacerbate psoriasis in a patient with chronic hepatitis C infection (Yurci et al., 2007) . Our data also showed that PBMCs stimulated with SA, but not non-NASA, produced a significant amount of IFN-a. Furthermore, the decreased IFN-a secretion could be reconstituted by the combined stimulation of non-NASA with CpG-A. In addition, consistent with the previous report (Nestle et al., 2005) , we observed a decreased pDC frequency in the peripheral blood from psoriatic patients. However, there was no significant difference in IFN-a production by PBMCs stimulated with SA between patients and healthy controls. Our data suggest that pDCs from psoriatic patients may have been activated, thus secreting large amounts of IFN-a. Indeed, it has been shown that the aberrant activation of pDCs triggers IFN-associated autoimmunity in psoriasis (Lande et al., 2007; Gilliet and Lande, 2008) .
We also noticed a lower T-cell proliferative response in the absence of pDCs compared with the whole antigenpresenting cells. However, T cells still proliferate in the absence of pDCs. Escherichia coli DNA has been shown to upregulate CD40 expression on human myeloid DCs, pDCs, and monocytes (Pichyangkul et al., 2001 ). Therefore, it is possible that when PBMCs are stimulated with SA, myeloid DCs or monocytes may inducibly express TLR-9 and costimulatory molecules to complement pDCs for T-cell proliferation. Further investigation is under way to confirm this result by enlarging sample sizes.
In addition, we did not observe any significant differences in IFN-g and TNF-a production by PBMCs from patients stimulated with SA and non-NASA. This may be attributable to other immunostimulatory components of streptococcus, such as peptidoglycan, which alternatively induce secretion of these cytokines (Takeda et al., 2003) .
We also found effects of streptococcal DNA on B-cell activation in cells from patients. However, no significant difference was found for the expression of CD86 on B cells stimulated with SA or non-NASA. In contrast to the enhanced T-cell activation mediated by non-NASA and CpG-A, the combined stimulation of non-NASA with CpG-B resulted in a significant upregulation of CD86 on B cells as compared with the non-NASA stimulation alone (data not shown). This result is perhaps due to the direct activation induced by CpG-B when B cells are stimulated with CpG-A or CpG-B, respectively. On the basis of the current findings, we conclude that streptococcal DNA has a similar effect on activating T cells as CpG-A, which may explain the role of streptococcal DNA in the development of psoriasis.
In conclusion, our study shows that SA without nucleic acid decreases the proliferation of PBMCs and activation of T cells, suggesting that streptococcal DNA may be complicit in the activation of pathogenic T cells, thus leading to the development of psoriasis.
MATERIALS AND METHODS

Patients
Patients with psoriasis vulgaris were diagnosed on the basis of clinical and histopathologic criteria (Schon and Boehncke, 2005) . PBMCs from 15 patients aged 10-70 years (mean 38±21) were used to assess the proliferation induced by various stimuli. In addition, PBMCs from a second set of 20 patients with similar characteristics (ages ranging from 10 to 77 years, mean 45±19) were used for flow cytometry analysis and ELISA. The patients had not been treated with systemic therapy for at least 4 weeks before study entry and were using only topical emollients. As controls, blood samples from 10 or 12 age-matched healthy volunteers were used. The study was approved by the Shanghai Jiao Tong University School of Medicine Research Ethics Committee and conducted according to the Declaration of Helsinki Principles. All the participants in this study gave their written informed consent.
Preparation of SA
SA was prepared from group A b-hemolytic streptococcus serotype M6 (catalog no. CMCC (B) 32175, China Centre for Type Culture Collection, Wuhan, Hubei, China). The bacteria were cultured on blood agar and incubated in Todd-Hewitt broth (Oxoid, Hampshire, UK) at 371C for 14-16 hours. After centrifugation, the pellets were washed twice in phosphate-buffered saline and then resuspended and sonicated. To prepare DNA-free SA (non-NASA), the SA was mixed with DNase-I (Roche Applied Science, Mannheim, Germany) to a final concentration of 1 mg ml À1 and incubated at 371C for 30 minutes. Complete digestion of bacterial DNA was confirmed by agarose gel electrophoresis. In some experiments, DNA-free SA was prepared by anion exchange chromatography (Q Sepharose XL; GE Healthcare, formerly Amersham Biosciences, Piscataway, NJ).
CpG ODNs
CpG ODNs were synthesized by Sigma-Genosys (St Louis, MO). All of the following sequences are 5 0 -3 0 ; lowercase letters are 5 0 of phosphothiorate linkages and uppercase letters are 5 0 of phosphodiester linkages. The sequences of the ODNs were CpG-A, ggTGCATCGATGCAGggggg, and CpG-B, tcgtcgttttgtcgttttgtcgtt.
Isolation of PBMCs
Human PBMCs were isolated from heparinized blood by density gradient centrifugation over Ficoll-Hypaque and resuspended in RPMI 1640 medium (GIBCO/Invitrogen, Life Technologies, Carlsbad, CA), supplemented with 10% fetal bovine serum, penicillin/streptomycin, 2 mM glutamine, and 25 mM HEPES (GIBCO/Invitrogen).
Isolation of peripheral T cells
PBMCs isolated from heparinized blood were suspended in sterile cell sorting medium containing 1 Â Hanks' balanced salt solution (GIBCO/ Invitrogen), 2% heat-inactivated fetal bovine serum (GIBCO/Invitrogen), 10 mM HEPES buffer (GIBCO/Invitrogen), and 30 mg ml À1 of gentamicin (GIBCO/Invitrogen). Cells were incubated with saturating concentrations of directly labeled anti-human CD3-PE-Cy5. 
Proliferation assay
Fresh PBMCs, or peripheral T cells in the presence of mitomycintreated antigen-presenting cells, were cultured in 96-well plates for 3 days with SA or non-NASA in a total volume of 200 ml. As a control, the maximal amount of DNase-I used in non-NASA was added to cultures of PBMCs with phytohemagglutinin (1 mg ml À1 ). Cultured cells were pulsed with 3 H-thymidine (1 mCi per well, Shanghai
Institute of Applied Physics, Chinese Academy of Science, Shanghai, China) 16 hours before cell harvest. Proliferation was determined by thymidine incorporation measured in a b-scintillation counter and expressed as the mean c.p.m. of three replicates.
Flow cytometry analysis
Fresh PBMCs from patients and healthy volunteers were cultured in 24-well plates for 24 hours with optimal concentrations of SA or non-NASA. PBMCs from patients were further stimulated with non-NASA plus CpG ODNs (5 mg ml À1 ) or CpG ODNs alone (5 mg ml À1 ).
To analyze CD69 expression on whole T cells or CLA þ T cells and CD86 on B cells from patients, PBMCs were stained with antihuman CD3-PE-Cy5 (clone UCHT1), anti-human CLA-FITC (clone HECA-452), and anti-human CD69-PE (clone FN50) or antihuman CD19-FITC (clone HIB19) and anti-human CD86-PE (clone 2331 (FUN-1) ) (all antibodies from BD Pharmingen, San Diego, CA) for 30 minutes on ice. Cells were washed twice with phosphatebuffered saline containing 3% fetal bovine serum, resuspended in 1% paraformaldehyde, and analyzed. A total of 20,000 events were analyzed per sample with the FACS Calibur (Becton Dickinson, San Jose, CA).
Detection of cytokines
Fresh PBMCs from patients were cultured in 24-well plates for 24 hours with optimal concentrations of SA and non-NASA. The culture supernatants were harvested and tested for the presence of cytokines IFN-a (Adlitteram Diagnostic Laboratories, San Diego, CA), IFN-g, and TNF-a (Diaclone, Stamford, CT) by ELISA.
Statistical analysis
Data were expressed as mean±SD of tested individuals. Statistical significance was determined using a paired t-test among patients or healthy individuals and the Student's t-test or non-parametric twotailed tests between patients and healthy individuals. Po0.05 was considered significant.
